{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:01:00Z","timestamp":1791900060000,"version":"4.3.4"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Long-acting injectable antipsychotics (LAIs) can help decrease the rate of nonadherence to medications in patients with schizophrenia, but these drugs are underutilized in clinical practice, especially in Asian countries. One strategy for the early prescription of LAIs is to administer the drugs during patients\u2019 first admission, when they have more time to absorb medication-related knowledge.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the prevalence of and risk factors for in-hospital use of LAIs among first-admission patients with schizophrenia in Taiwan and to examine the association of early discontinuation with readmission risk among patients receiving LAIs.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study included data from a claims database for patients with a first admission for schizophrenia at psychiatric wards in Taiwan from 2004 to 2017. Eligible patients were diagnosed with schizophrenia or schizoaffective disorder at discharge and aged between 15 and 64 years. Data analysis was performed from April to September 2022.<\/jats:p><\/jats:sec>Exposure<\/jats:title>In-hospital use of LAIs with or without early discontinuation.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>Readmission for any psychotic disorder following discharge from first admission, with risk estimated via multivariable survival regression analysis, including the Cox proportional hazards (CPH) model and accelerated failure time (AFT) model.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 56\u202f211 patients with a first admission for schizophrenia (mean [SD] age, 38.1 [12.1] years; 29\u202f387 men [52.3%]), 46\u202f875 (83.4%) did not receive any LAIs during admission, 5665 (10.1%) received LAIs with early discontinuation, and 3671 (6.5%) received LAIs without early discontinuation. The prevalence of receiving LAIs increased by 4%, from 15.3% (3863 of 25\u202f251 patients) to 19.3% (3013 of 15\u202f608 patients) between 2004-2008 and 2013-2017. After controlling for sex, year, prior antipsychotic use, age at first admission, and length of stay, the CPH regression analysis revealed that the readmission risk increased among patients receiving LAIs with early discontinuation (adjusted hazard ratio [aHR], 1.25; 95% CI, 1.21-1.30) but decreased among patients receiving LAIs without early discontinuation (aHR, 0.88; 95% CI, 0.84-0.92) compared with patients not receiving LAIs. Results remained similar for the AFT model.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The incidence of in-hospital use of LAIs among patients with a first admission for schizophrenia has remained low. In this study, early discontinuation of LAIs was associated with readmission risk\u2014specifically, early discontinuation with a higher risk while the lack of early discontinuation with a lower risk compared with treatment with oral antipsychotics alone\u2014which suggests our results have implications for improving the efficacy of LAI administration among patients with a first admission for schizophrenia.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.17006","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T15:34:50Z","timestamp":1718638490000},"page":"e2417006","source":"Crossref","is-referenced-by-count":13,"title":["In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan"],"prefix":"10.1001","volume":"7","author":[{"given":"Wei","family":"Chen","sequence":"first","affiliation":[{"name":"Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Shin","family":"Wu","sequence":"additional","affiliation":[{"name":"National Center for Geriatrics and Welfare Research, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chung","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine and National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hsiu","family":"Kuo","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Psychiatry, College of Medicine and National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yu","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine and National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan"},{"name":"Taoyuan Psychiatric Center, Ministry of Health and Welfare, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chu Ella","family":"Chung","sequence":"additional","affiliation":[{"name":"Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei J.","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Psychiatry, College of Medicine and National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan"},{"name":"Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"issue":"9","key":"zoi240558r1","first-page":"638","article-title":"Schizophrenia: overview and treatment options.","volume":"39","author":"Patel","year":"2014","journal-title":"P T"},{"issue":"3","key":"zoi240558r2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"zoi240558r3","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.jclinepi.2013.01.012","article-title":"Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry.","volume":"66","author":"Kane","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"zoi240558r4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/13696998.2019.1615927","article-title":"Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.","volume":"22","author":"Song","year":"2019","journal-title":"J Med Econ"},{"issue":"7","key":"zoi240558r5","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1007\/s12325-020-01396-w","article-title":"Treatment persistence between long-acting injectable versus orally administered aripiprazole among patients with schizophrenia in a real-world clinical setting in Japan.","volume":"37","author":"Iwata","year":"2020","journal-title":"Adv Ther"},{"issue":"9","key":"zoi240558r6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14656566.2021.1882996","article-title":"Improving adherence to pharmacological treatment for schizophrenia: a systematic assessment.","volume":"22","author":"Curto","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"2-3","key":"zoi240558r7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","article-title":"Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics.","volume":"176","author":"Misawa","year":"2016","journal-title":"Schizophr Res"},{"issue":"5","key":"zoi240558r8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"zoi240558r9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia.","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"zoi240558r10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","article-title":"Antipsychotics and mortality in a nationwide cohort of 29823 patients with schizophrenia.","volume":"197","author":"Taipale","year":"2018","journal-title":"Schizophr Res"},{"issue":"10","key":"zoi240558r11","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.4088\/JCP.09m05284yel","article-title":"A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.","volume":"70","author":"Weiden","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"zoi240558r12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial.","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"zoi240558r13","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial.","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"zoi240558r14","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1017\/S0033291720003335","article-title":"A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work\/school functioning.","volume":"52","author":"Nuechterlein","year":"2022","journal-title":"Psychol Med"},{"issue":"9","key":"zoi240558r15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.euroneuro.2019.07.138","article-title":"Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: a nationwide population-based study.","volume":"29","author":"Joo","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"zoi240558r16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/schbul\/sbac046","article-title":"Comparative effectiveness of antipsychotics in preventing readmission for first-admission schizophrenia patients in national cohorts from 2001 to 2017 in Taiwan.","volume":"48","author":"Lin","year":"2022","journal-title":"Schizophr Bull"},{"issue":"4","key":"zoi240558r17","doi-asserted-by":"publisher","DOI":"10.1111\/appy.v12.4","article-title":"Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region.","volume":"12","author":"Tang","year":"2020","journal-title":"Asia Pac Psychiatry"},{"key":"zoi240558r18","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2147\/NDT.S413371","article-title":"Long-acting injectable antipsychotic treatment for schizophrenia in Asian population: a scoping review.","volume":"19","author":"Ma","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"zoi240558r19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence.","volume":"77","author":"Correll","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"zoi240558r20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/JCP.0000000000001225","article-title":"Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of schizophrenia.","volume":"40","author":"Lindenmayer","year":"2020","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"zoi240558r21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/pcn.2019.73.issue-5","article-title":"Discontinuation rates during long-term, second-generation antipsychotic long-acting injection treatment: a systematic review.","volume":"73","author":"Gentile","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"issue":"9","key":"zoi240558r22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.18553\/jmcp.2015.21.9.754","article-title":"Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge.","volume":"21","author":"Marcus","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"zoi240558r23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/YIC.0000000000000165","article-title":"Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.","volume":"32","author":"Kishimoto","year":"2017","journal-title":"Int Clin Psychopharmacol"},{"key":"zoi240558r24","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8629030","article-title":"Use of long-acting injectable antipsychotic in an inpatient unit of a community teaching hospital.","volume":"2019","author":"Olayinka","year":"2019","journal-title":"Psychiatry J"},{"issue":"3","key":"zoi240558r25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/jpm12030441","article-title":"Use of long-acting injectable antipsychotics in inpatients with schizophrenia spectrum disorder in an academic psychiatric hospital in Switzerland.","volume":"12","author":"Reymann","year":"2022","journal-title":"J Pers Med"},{"key":"zoi240558r26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP","article-title":"Taiwan\u2019s National Health Insurance Research Database: past and future.","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"key":"zoi240558r27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jad.2016.03.043","article-title":"Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder.","volume":"197","author":"Wu","year":"2016","journal-title":"J Affect Disord"},{"issue":"1-3","key":"zoi240558r28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.schres.2015.10.013","article-title":"Gender differences in the treatment of first-episode schizophrenia: results from the European First Episode Schizophrenia Trial.","volume":"169","author":"Ceskova","year":"2015","journal-title":"Schizophr Res"},{"key":"zoi240558r29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.schres.2022.12.011","article-title":"Sex and pubertal influences on the neurodevelopmental underpinnings of schizophrenia: a case for longitudinal research on adolescents.","volume":"252","author":"Barendse","year":"2023","journal-title":"Schizophr Res"},{"issue":"1","key":"zoi240558r30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology.","volume":"34","author":"Barnes","year":"2020","journal-title":"J Psychopharmacol"},{"issue":"5","key":"zoi240558r31","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"issue":"9","key":"zoi240558r32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/0706743717719894","article-title":"Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults.","volume":"62","author":"Norman","year":"2017","journal-title":"Can J Psychiatry"},{"issue":"8","key":"zoi240558r33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40263-021-00838-5","article-title":"Evidence-based expert consensus regarding long-acting injectable antipsychotics for schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN).","volume":"35","author":"Yang","year":"2021","journal-title":"CNS Drugs"},{"issue":"3","key":"zoi240558r34","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12546","article-title":"Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial.","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"zoi240558r35","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial Is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"2-3","key":"zoi240558r36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.schres.2016.07.012","article-title":"Interrater reliability of schizoaffective disorder compared with schizophrenia, bipolar disorder, and unipolar depression\u2014a systematic review and meta-analysis.","volume":"176","author":"Santelmann","year":"2016","journal-title":"Schizophr Res"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2820091\/chen_2024_oi_240558_1718024070.67583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T15:34:53Z","timestamp":1718638493000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2820091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.17006","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]}}}